AGM Statement

AI SummaryClose X

Anpario plc reported a positive start to the year with revenue and profit exceeding prior year performance and meeting analyst consensus expectations, despite geopolitical and economic challenges. The company saw strong trading in the Middle East, including sales of its new product AmpLIPhy, and continued growth in the US and Australasia. While initial logistics cost increases were absorbed, ongoing higher costs and some raw material price inflation, particularly in its acid-based eubiotic range (20% of sales), have been largely passed on to customers through targeted price rises, maintaining first-half gross margins consistent with the second half of 2025. Anpario also repurchased £2.0m of shares under a £3.0m buyback program, adding to its bi-annual dividend payments of £2.1m last year, and maintained a strong cash balance of £10.9m as of May 31, 2026.

Disclaimer*

Companies

Anpario (ANP)
UK 100

Latest directors dealings